HUP0101326A2 - Paroxetinkompozíciók és eljárás az előállításukra - Google Patents

Paroxetinkompozíciók és eljárás az előállításukra

Info

Publication number
HUP0101326A2
HUP0101326A2 HU0101326A HUP0101326A HUP0101326A2 HU P0101326 A2 HUP0101326 A2 HU P0101326A2 HU 0101326 A HU0101326 A HU 0101326A HU P0101326 A HUP0101326 A HU P0101326A HU P0101326 A2 HUP0101326 A2 HU P0101326A2
Authority
HU
Hungary
Prior art keywords
paroxetine
pharmaceutically acceptable
absorbed
adsorbed
derivative
Prior art date
Application number
HU0101326A
Other languages
English (en)
Inventor
Andrew Simon Craig
Neal Ward
Original Assignee
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc. filed Critical Smithkline Beecham Plc.
Publication of HUP0101326A2 publication Critical patent/HUP0101326A2/hu
Publication of HUP0101326A3 publication Critical patent/HUP0101326A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány szilárd hordozón adszerbeált vagy szilárd hordozó általabszorbeált paroxetinre vagy gyógyászatilag elfogadhatóparoxetinszármazékra, valamint a termék előállítási eljárásáravonatkozik. A találmány kiterjed továbbá a következőkre: -gyógyszerkészítmény a leírásban meghatározott rendellenességek,különösen depresszió kezelésére vagy megelőzésére, amely szilárdhordozón adszorbeált vagy szilárd hordozó által abszorbeált paroxetintvagy gyógyászatilag elfogadható paroxetinszármazékot, valamint adottesetben legalább egy gyógyászatilag elfogadható hordozót tartalmaz; -szilárd hordozón adszorbeált vagy szilárd hordozó által abszorbeáltparoxetin vagy gyógyászatilag elfogadható paroxetinszármazékalkalmazása a leírásban meghatározott rendellenességek, különösendepresszió kezelésére vagy megelőzésére szolgáló gyógyszerkészítményelőállítására; és - eljárás a leírásban meghatározottrendellenességek, különösen depresszió kezelésére, amelynek során egyegy vagy több rendellenességben szenvedő betegnek szilárd hordozónadszorbeált vagy szilárd hordozó által abszorbeált paroxetin vagygyógyászatilag elfogadható paroxetinszármazék hatásos vagyprofilaktikus mennyiségét adják be. Ó
HU0101326A 1998-03-24 1999-03-24 Paroxetine compositions and process for their preparation HUP0101326A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806312.6A GB9806312D0 (en) 1998-03-24 1998-03-24 Novel formulations

Publications (2)

Publication Number Publication Date
HUP0101326A2 true HUP0101326A2 (hu) 2002-05-29
HUP0101326A3 HUP0101326A3 (en) 2002-06-28

Family

ID=10829181

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101326A HUP0101326A3 (en) 1998-03-24 1999-03-24 Paroxetine compositions and process for their preparation

Country Status (20)

Country Link
EP (1) EP1063993A1 (hu)
JP (1) JP2002507569A (hu)
CN (1) CN1125639C (hu)
AP (1) AP2000001914A0 (hu)
AU (1) AU754765B2 (hu)
BG (1) BG104865A (hu)
BR (1) BR9908991A (hu)
CA (1) CA2324612A1 (hu)
EA (1) EA003393B1 (hu)
GB (1) GB9806312D0 (hu)
HU (1) HUP0101326A3 (hu)
ID (1) ID26485A (hu)
IL (1) IL138478A0 (hu)
NO (1) NO313404B1 (hu)
NZ (1) NZ506893A (hu)
PL (1) PL343095A1 (hu)
SK (1) SK14102000A3 (hu)
TR (1) TR200002750T2 (hu)
WO (1) WO1999048499A1 (hu)
ZA (1) ZA200005697B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914600D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel,process
DK200100341A (da) * 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Fremgangsmåde til fremstilling af farmaceutiske tabletter indeholdende paroxetinhydrochlorid-anhydrat
EP1643975A2 (en) * 2003-07-02 2006-04-12 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US8062664B2 (en) 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
HU1000278D0 (en) * 2010-05-28 2010-07-28 Egis Gyogyszergyar Nyilvanosan Novel pharmaceutical use uf silicic acid
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride

Also Published As

Publication number Publication date
AU754765B2 (en) 2002-11-21
EP1063993A1 (en) 2001-01-03
NO313404B1 (no) 2002-09-30
IL138478A0 (en) 2001-10-31
CA2324612A1 (en) 1999-09-30
AU3045199A (en) 1999-10-18
BG104865A (en) 2001-05-31
TR200002750T2 (tr) 2000-12-21
ID26485A (id) 2001-01-11
CN1125639C (zh) 2003-10-29
WO1999048499A1 (en) 1999-09-30
NO20004740L (no) 2000-10-03
JP2002507569A (ja) 2002-03-12
SK14102000A3 (sk) 2001-03-12
PL343095A1 (en) 2001-07-30
BR9908991A (pt) 2000-12-12
EA200000977A1 (ru) 2001-02-26
NZ506893A (en) 2003-06-30
AP2000001914A0 (en) 2000-09-30
CN1294512A (zh) 2001-05-09
HUP0101326A3 (en) 2002-06-28
EA003393B1 (ru) 2003-04-24
ZA200005697B (en) 2001-10-02
GB9806312D0 (en) 1998-05-20
NO20004740D0 (no) 2000-09-22

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
SE9503924D0 (sv) Novel opioid peptides
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
HUP0200309A3 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
PH31335A (en) Naphthalamides as central nervous system agent.
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
HUP0200284A2 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
EP1057828A3 (en) Trovafloxacin oral suspensions
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer
SI1274685T1 (sl) Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
HUP0101326A2 (hu) Paroxetinkompozíciók és eljárás az előállításukra
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
IL129627A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
WO2001023385A3 (en) Novel tropane analogs
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees